Antineoplastic Agents

"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Substances that inhibit or prevent the proliferation of NEOPLASMS.

Descriptor ID	D000970
MeSH Number(s)	D27.505.954.248
Concept/Terms	Antineoplastic Agents Antineoplastic Agents Agents, Antineoplastic Antineoplastic Drugs Drugs, Antineoplastic Antineoplastics Chemotherapeutic Anticancer Drug Drug, Chemotherapeutic Anticancer Antitumor Drugs Drugs, Antitumor Cancer Chemotherapy Agents Agents, Cancer Chemotherapy Chemotherapy Agents, Cancer Cancer Chemotherapy Drugs Chemotherapy Drugs, Cancer Drugs, Cancer Chemotherapy Chemotherapeutic Anticancer Agents Agents, Chemotherapeutic Anticancer Anticancer Agents Agents, Anticancer Antitumor Agents Agents, Antitumor

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.

Bar chart showing 6755 publications over 31 distinct years, with a maximum of 403 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	26	5	31
1993	34	10	44
1994	43	13	56
1995	29	17	46
1996	53	18	71
1997	53	22	75
1998	59	21	80
1999	76	27	103
2000	82	39	121
2001	92	42	134
2002	131	63	194
2003	146	62	208
2004	154	72	226
2005	157	61	218
2006	176	96	272
2007	199	113	312
2008	198	103	301
2009	203	119	322
2010	244	131	375
2011	249	145	394
2012	247	106	353
2013	240	116	356
2014	256	99	355
2015	290	113	403
2016	246	125	371
2017	226	98	324
2018	188	81	269
2019	160	79	239
2020	158	61	219
2021	168	54	222
2022	54	7	61

Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.

Rodwin RL, Kairalla JA, Hibbitts E, Devidas M, Whitley MK, Mohrmann CE, Schore RJ, Raetz E, Winick NJ, Hunger SP, Loh ML, Hockenberry MJ, Angiolillo AL, Ness KK, Kadan-Lottick NS. Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia. J Natl Cancer Inst. 2022 Aug 08; 114(8):1167-1175.

View in: PubMed
Ramnarine SR, Dougherty PM, Rolke R, Williams LJ, Alessi-Fox C, Coleman AJ, Longo C, Colvin LA, Fallon MT. The Value of In Vivo Reflectance Confocal Microscopy as an Assessment Tool in Chemotherapy-Induced Peripheral Neuropathy: A Pilot Study. Oncologist. 2022 Aug 05; 27(8):e671-e680.

View in: PubMed
García-Gutiérrez V, Breccia M, Jabbour E, Mauro M, Cortes JE. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. J Hematol Oncol. 2022 07 11; 15(1):90.

View in: PubMed
Barekatain Y, Khadka S, Harris K, Delacerda J, Yan VC, Chen KC, Pham CD, Uddin MN, Avritcher R, Eisenberg EJ, Kalluri R, Millward SW, Muller FL. Quantification of Phosphonate Drugs by 1H-31P HSQC Shows That Rats Are Better Models of Primate Drug Exposure than Mice. Anal Chem. 2022 07 19; 94(28):10045-10053.

View in: PubMed
Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022 08; 23(8):1055-1065.

View in: PubMed
Ngoi NYL, Westin SN, Yap TA. Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations. Curr Opin Oncol. 2022 Sep 01; 34(5):559-569.

View in: PubMed
Short NJ, Kantarjian H. Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia. Lancet Haematol. 2022 Jul; 9(7):e535-e545.

View in: PubMed
Koutroumpakis E, Agrawal N, Palaskas NL, Abe JI, Iliescu C, Yusuf SW, Deswal A. Myocardial Dysfunction in Patients with Cancer. Heart Fail Clin. 2022 Jul; 18(3):361-374.

View in: PubMed
Kroll MH, Rojas-Hernandez C, Yee C. Hematologic complications of immune checkpoint inhibitors. Blood. 2022 06 23; 139(25):3594-3604.

View in: PubMed
Adimora IJ, Wilson NR, Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics. Cancer. 2022 08 15; 128(16):3019-3026.

View in: PubMed

People

Explore

Similar Concepts

Top Journals